Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression |
Zhou, Da
(Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine)
Chen, Yuan-Wen (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Zhao, Ze-Hua (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Yang, Rui-Xu (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Xin, Feng-Zhi (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Liu, Xiao-Lin (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Pan, Qin (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) Zhou, Huiping (Department of Microbiology and Immunology, Department of Internal Medicine/GI Division, McGuire VA Medical Center) Fan, Jian-Gao (Center for Fatty Liver, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) |
1 | Wang, F. S., Fan, J. G., Zhang, Z., Gao, B. & Wang, H. Y. The global burden of liver disease: the major impact of China. Hepatology 60, 2099-2108 (2014). DOI |
2 | Fan, J. G., Kim, S. U. & Wong, V. W. Newtrends on obesity and NAFLD in Asia. J. Hepatol. 67, 862-873 (2017). DOI |
3 | Rinella, M. E. Nonalcoholic fatty liver disease. JAMA 313, 2263 (2015). DOI |
4 | Park, J. S., Lee, E. J., Lee, J. C., Kim, W. K. & Kim, H. S. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int. Immunopharmacol. 7, 70-77 (2007). DOI |
5 | Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509-1517 (2009). DOI |
6 | Dhir, G. & Cusi, K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. J. Invest. Med. 66, 7-10 (2018). DOI |
7 | Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364-371 (2012). DOI |
8 | Ohira, H., Tsutsui, W. & Fujioka, Y. Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? J. Atheroscler. Thromb. 24, 660-672 (2017). DOI |
9 | Ding, X., Saxena, N. K., Lin, S., Gupta, N. A. & Anania, F. A. Exendin-4, a glucagonlike protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43, 173-181 (2006). DOI |
10 | Gupta, N. A. et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584-1592 (2010). DOI |
11 | Smits, M. M. et al. GLP-1 based therapies: clinical implications for gastroenterologists. Gut 65, 702-711 (2016). DOI |
12 | Clarke, G. et al. Minireview: gut microbiota: the neglected endocrine organ. Mol. Endocrinol. 28, 1221-1238 (2014). DOI |
13 | Tremaroli, V. & Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242-249 (2012). DOI |
14 | Zhou, D. et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J. Gastroenterol. 23, 60-75 (2017). DOI |
15 | Wen, Z.-S., Lu, J.-J. & Zou, X.-T. Effects of sodium butyrate on the intestinal morphology and DNA-binding activity of intestinal nuclear factor-:EB in weanling pigs. J. Anim. Vet. Adv. 11, 814-821 (2012). DOI |
16 | Yadav, H., Lee, J. H., Lloyd, J., Walter, P. & Rane, S. G. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288, 25088-25097 (2013). DOI |
17 | Chambers, E. S., Morrison, D. J. & Frost, G. Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? Proc. Nutr. Soc. 74, 328-336 (2015). DOI |
18 | Zhou, D. et al. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J. Gastroenterol. Hepatol. 32, 1640-1648 (2017). DOI |
19 | Kaji, I., Karaki, S.-i & Kuwahara, A. Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 89, 31-36 (2014). DOI |
20 | Cd, Graaf et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev. 68, 954-1013 (2016). DOI |
21 | Zhang, W. H. et al. Sodium butyrate maintains growth performance by regulating the immune response in broiler chickens. Br. Poult. Sci. 52, 292-301 (2011). DOI |
22 | Ben-Shlomo, S. et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J. Hepatol. 54, 1214-1223 (2011). DOI |
23 | Guilloteau, P. et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr. Res. Rev. 23, 366-384 (2010). DOI |
24 | den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325-2340 (2013). DOI |
25 | Gkolfakis, P., Dimitriadis, G. & Triantafyllou, K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 14, 572-581 (2015). DOI |
26 | Marchesi, J. R. et al. The gut microbiota and host health: a new clinical frontier. Gut 65, 330-339 (2016). DOI |
27 | Steliou, K., Boosalis, M. S., Perrine, S. P., Sangerman, J. & Faller, D. V. Butyrate histone deacetylase inhibitors. Biores. Open Access 1, 192-198 (2012). DOI |
28 | Cleophas, M. C. et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann. Rheum. Dis. 75, 593-600 (2016). |
29 | Trevaskis, J. L. et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G762-G772 (2012). DOI |
30 | Svegliati-Baroni, G. et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31, 1285-1297 (2011). DOI |
31 | Ao, N., Yang, J., Wang, X. & Du, J. Glucagon-like peptide-1 preserves nonalcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol. Res. 46, 343-353 (2016). DOI |
32 | Tang, A. et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial. Diabetes Care 38, 1339-1346 (2015). DOI |
33 | Smits, M. M. et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia 59, 2588-2593 (2016). DOI |
34 | Zhou, D. et al. Prolyl oligopeptidase inhibition attenuates steatosis in the L02 human liver cell line. PLoS ONE 11, e0165224 (2016). DOI |
35 | Grasset, E. et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell. Metab. 25, 1075-1090 e5 (2017). DOI |
36 | Bedossa, P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60, 565-575 (2014). DOI |
37 | Gomez-Lechon, M. J. et al. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 165, 106-116 (2007). DOI |
38 | Zhou, D. et al. Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci. Rep. 7, 1529 (2017). DOI |
39 | Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005). DOI |
![]() |